Mountain Sickness Clinical Trial
Official title:
Randomized Controlled Trial of N-acetylcysteine and Acetazolamide in Treatment of Chronic Mountain Sickness
Chronic mountain sickness is characterized by excessive red blood cell production which causes sludging of the vascular system. This high viscosity blood causes heart failure, cognitive dysfunction, and strokes. The investigators hypothesize that cobalt which has been previously been shown to be an environmental pollutant worsens the overproduction of red blood cells. The investigators plan to conduct a 6 week trial in which acetazolamide (already shown to improve chronic mountain sickness) and N-acetylcysteine (a drug that removes cobalt from the blood) are evaluated in their potential to improve chronic mountain sickness.
n/a
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Active, not recruiting |
NCT01182792 -
Chronic Mountain Sickness, Systemic Vascular Function
|
N/A | |
| Completed |
NCT00952302 -
Study of the Effects of Iron Levels on the Lungs at High Altitude
|
N/A | |
| Completed |
NCT04075565 -
The Psychophysiological Effect of Simulated and Terrestrial Altitude
|
N/A | |
| Completed |
NCT01587027 -
Safety Evaluation of Aminophylline and Methazolamide
|
Phase 1 | |
| Not yet recruiting |
NCT06129825 -
Pharmacologic Induction of Tolerance for Hypoxia & Hypothermia
|
||
| Completed |
NCT02463357 -
Three New Ideas to Protect Special Forces From the Stress of High Altitude
|
Phase 4 |